McKesson Strengthens Its Portfolio of Manufacturer Solutions with the Acquisition of RxCrossroads

Go back to McKesson Strengthens Its Portfolio of Manufacturer Solutions with the Acquisition of RxCrossroads

CVS Health (CVS) PT Lowered to $76 at Jefferies Following 3Q

November 7, 2017 8:24 AM EST

Jefferies lowered its price target on CVS Health (NYSE: CVS) to $76.00 (from $86.00) while maintaining a Hold rating. CVS reported Q3 EPS of $1.50 that beat consensus by $0.02. Similar to the last few quarters, SSS revs were pressured by weakness in front-end sales and the... More